Refine
Has Fulltext
- yes (6)
Is part of the Bibliography
- yes (6)
Document Type
- Journal article (6)
Language
- English (6) (remove)
Keywords
- ARONJ (2)
- Haemophilus influenzae (2)
- osteonecrosis of the jaw (2)
- osteoradionecrosis (2)
- COVID-19 testing (1)
- COVID‐19 vaccination (1)
- Elderly (1)
- Geriatric care (1)
- Geriatrics (1)
- Germany (1)
- MRONJ (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Neisseria meningitidis (1)
- Nursing homes (1)
- ONJ (1)
- SARS‐CoV‐2 infection (1)
- Staphylococcus aureus (1)
- agar (1)
- agar diffusion test (1)
- ampicillin (1)
- antibiotic bone concentration (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- anti‐SARS‐CoV‐2‐spike IgG (1)
- attitude of health personnel (1)
- beta-lactam (1)
- feasibility study (1)
- general practice (1)
- generalized anxiety disorder (1)
- haemophilus influenzae (1)
- healthcare workers (1)
- immunology (1)
- jaw bone (1)
- microbiology (1)
- oral microbiome (1)
- piperacillin (1)
- piperacillin/tazobactam (1)
- sensitivity and specificity (1)
- seroprevalence (1)
- tazobactam (1)
Institute
- Institut für Hygiene und Mikrobiologie (5)
- Institut für Pharmazie und Lebensmittelchemie (2)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (2)
- Institut für Allgemeinmedizin (1)
- Institut für Virologie und Immunbiologie (1)
- Medizinische Klinik und Poliklinik I (1)
- Medizinische Klinik und Poliklinik II (1)
Background
Haemophilus influenzae (Hi) is a Gram-negative bacterium that may cause sepsis or meningitis, treatment of which mainly includes β-lactam antibiotics. Since 2019 EUCAST breakpoints for piperacillin/tazobactam have been available. Little is known about the prevalence and mechanisms of piperacillin/tazobactam resistance in Hi.
Objectives
To provide reliable prevalence data for piperacillin/tazobactam resistance in Hi in Germany, to evaluate different antibiotic susceptibility testing methods and to examine possible resistance mechanisms.
Methods
According to EUCAST breakpoints, the MIC for piperacillin/tazobactam resistance is >0.25 mg/L. All invasive Hi in Germany from 2019 were examined by gradient agar diffusion (GAD) for piperacillin/tazobactam susceptibility. Piperacillin/tazobactam broth microdilution (BMD), piperacillin GAD on tazobactam-containing agar [piperacillin GAD on Mueller–Hinton agar with horse blood (MH-F)/tazobactam) and piperacillin/tazobactam agar dilution (AD) were used for confirmation. Phenotypic testing was complemented by ftsI sequencing.
Results
Piperacillin/tazobactam GAD resulted in 2.9% (21/726) resistant Hi. BMD did not confirm piperacillin/tazobactam resistance. Two strains were found resistant by AD, of which one was also resistant using piperacillin GAD on MH-F/tazobactam. Overall, we found two strains with a piperacillin/tazobactam MIC >0.25 mg/L in at least two different tests (0.3%). Both were β-lactamase-producing amoxicillin/clavulanate-resistant with PBP3 mutations characterized as group III-like+. Relevant PBP3 mutations occurred in six strains without phenotypic piperacillin/tazobactam resistance. These mutations suggest a reduced efficacy of β-lactam antibiotics in these isolates.
Conclusions
Piperacillin/tazobactam resistance prevalence in invasive Hi is low in Germany. Reduced susceptibility was correlated with PBP3 mutations, in particular with group III mutations.